Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

2885 - Genetic screening, counselling, and treatment of BRCA mutation (BRCAm) carriers: a systematic review (SR) of international breast cancer (BC) guidelines

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Cancer Prevention;  Targeted Therapy;  Genetic and Genomic Testing, Counseling

Tumour Site

Breast Cancer

Presenters

Carol Forbes

Citation

Annals of Oncology (2018) 29 (suppl_8): viii90-viii121. 10.1093/annonc/mdy272

Authors

C. Forbes1, D. Fayter1, C. Clar1, K. Reid1, S. de Kock1, R. Quek2

Author affiliations

  • 1 Health Economics, Kleijnen Systematic Reviews Ltd, YO19 6FD - York/GB
  • 2 Health Economics, Pfizer, Inc., 94080 - San Francisco/US
More

Resources

Abstract 2885

Background

Considering the availability of BRCAm-targeted therapeutic drugs in BC and an evolving clinical guidelines landscape, an SR of international guidelines on screening and management of BRCAm BC patients was carried out.

Methods

The current SR adhered to Cochrane’s guidance. Major electronic databases (eg, Medline & Embase; n = 7) and grey literature sources were searched (Jan 2007 to Dec 2017). Latest guideline reporting recommendations (and evidence grades) on genetic screening, counselling, and BC treatment of BRCAm carriers were summarised. Guidelines specific to germline (gBRCAm) (ie, hereditary) were captured where available.

Results

3775 records were retrieved and 33 guidelines from Europe (n = 17), USA (n = 11), Canada (n = 3), Australia (n = 1), and Japan (n = 1) were included. Genetic counselling was recommended at multiple points in the care pathway, though the format (eg, frequency, decision tools) was not always clearly defined. US guidelines emphasised BRCAm testing should occur after specialised genetic counselling; other European guidelines were less prescriptive. BRCA testing eligibility criteria differed with some guidelines being less restrictive; US NCCN BC guidelines specified that HER2- BC patients eligible for single-agent therapy should strongly consider gBRCAm testing, while also having separate more restrictive high-risk BRCA testing criteria. Similar restrictive criteria were observed in some European guidelines. Fast-track BRCAm testing was recommended in the Netherlands if treatment choice affects BC survival, but only as part of a clinical trial in the UK. Other guidelines suggest testing only if it affects therapy decisions. ESMO ABC3 guidelines recommended platinum therapy for advanced BRCAm BC; more recent ESO-ESMO BCY3 and US NCCN guidelines recommended newly approved gBRCAm-targeted PARP inhibitor therapy.

Conclusions

Differences exist between regions and within organizations for guidelines regarding genetic screening, counselling, and treatment of BRCAm BC patients. Harmonisation of guidelines could optimise the identification and management of BRCAm BC patients.

Clinical trial identification

Legal entity responsible for the study

Pfizer, Inc.

Funding

Pfizer, Inc.

Editorial Acknowledgement

Editorial and medical writing support funded by Pfizer Inc. were provided by Edwin Thrower, PhD, Mary Kacillas and Paula Stuckart of Ashfield Healthcare Communications, Middletown, Connecticut.

Disclosure

C. Forbes, D. Fayter, S. de Kock: Employee: KSR Ltd. who were paid by Pfizer Inc. to carry out this work. C. Clar, K. Reid: Freelance reviewer working on behalf of KSR Ltd. who were paid by KSR Ltd to carry out this work. R. Quek: Employee: Pfizer Inc.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.